ReviewHematology. American Society of Hematology. Education Program2018
Autoimmune hemolytic anemia.
Review in Hematology. American Society of Hematology. Education Program, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04083014 (An Open, One-arm, Prospective Study of a Single Dose Anti-CD20 Monoclonal Antibody Combined With Bortezomib for Treatment of Relapsed Refractory Autoimmune Hemolytic Anemia), which is not on this map. Cited by 84 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open, One-arm, Prospective Study of a Single Dose Anti-CD20 Monoclonal Antibody Combined With Bortezomib for Treatment of Relapsed Refractory Autoimmune Hemolytic Anemia
Who cites it
84 citing papers in PubMed, 4 syntheses or guidelines pooled it, 167 citations in OpenAlex.
- Mixed Autoimmune Hemolytic Anemia: A Systematic Review of Epidemiology, Clinical Characteristics, Therapies, and Outcomes.American journal of hematology · 2025Pooled it
- The Role of Nutrition in COVID-19 Susceptibility and Severity of Disease: A Systematic Review.The Journal of nutrition · 2021Pooled it
- Disease-modifying treatments for primary autoimmune haemolytic anaemia.The Cochrane database of systematic reviews · 2021Pooled it
- Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment.Blood advances · 2019Pooled it
- Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors.American journal of hematology · 2019Trial
- Unraveling the Cause of Hemolytic Anemia in the Emergency Department: A Destructive Path.Cureus · 2026Article
- Article
- A Case Report of a 14-year-old Boy with Mixed-type Autoimmune Hemolytic Anemia.Annals of African medicine · 2026Article
- Efficacy of belimumab in patients with SLE and haematological manifestations: retrospective analysis from the BeRLiSS 2.0 cohort.Lupus science & medicine · 2026Article
- Three Faces of Self-Destruction: A Case Series of Warm, Cold, and Mixed Autoimmune Hemolytic Anemia.Cureus · 2026Article
- Hematologic and coagulation responses to Johnson & Johnson COVID-19 vaccination in the Amhara region, Ethiopia.Scientific reports · 2026Article
- Article
- Babesiosis-induced warm autoimmune hemolytic anemia, from infection to hemolysis: a case report.Journal of medical case reports · 2025Review
- Article
- Article
- Evans Syndrome and COVID-19 Infection or Vaccination: A Systematic Review of Case Reports.Journal of hematology · 2025Review
- Prevalence of systemic lupus erythematosus in autoimmune hemolytic anemia patients based on coombs test results.European journal of medical research · 2025Article
- Cytopenias in Autoimmune Liver Diseases-A Review.Journal of clinical medicine · 2025Review
- Case Report: Coexisting cold agglutinin disease and acquired hemophilia A: a rituximab-responsive dual autoimmune disorder.Frontiers in medicine · 2025Article
- Methimazole-Induced Pancytopenia in a Patient with Graves' Disease: A Case Report and Literature Review.Current drug safety · 2025Review
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnosis of autoimmune hemolytic anemia (AIHA) can be made with a stepwise approach that aims to identify laboratory and clinical evidence of hemolysis and then determine the immune nature of hemolysis with the direct anti-globulin test. Once alternative causes for these findings have been excluded, AIHA is established, and the clinician must search for secondary causes, as well as identify the type of AIHA. Rituximab is now the preferred second-line treatment for primary warm AIHA and first-line treatment for primary cold agglutinin disease (CAD), either as monotherapy or combined with bendamustine. Complement inhibitors have shown utility in stabilizing AIHA patients with acute severe hemolysis. Future prospects are discussed and include the C1s inhibitor BIVV009 (sutimlimab) that is now entering phase 3 studies for CAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.